Inhibition of Calpain Activation Protects MPTP-Induced Nigral and Spinal Cord Neurodegeneration, Reduces Inflammation, and Improves Gait Dynamics in Mice
- 25 June 2015
- journal article
- research article
- Published by Springer Nature in Molecular Neurobiology
- Vol. 52 (2) , 1054-1066
Abstract
Parkinson’s disease (PD) is the most common neurodegenerative movement disorder, resulting in dopaminergic (DA) neuronal loss in the substantia nigra pars compacta (SNpc) and damage to the extranigral spinal cord neurons. Current therapies do not prevent the disease progression. Hence, developing efficacious therapeutic strategies for treatment of PD is of utmost importance. The goal of this study is to delineate the involvement of calpain-mediated inflammation and neurodegeneration in SN and spinal cord in MPTP-induced parkinsonian mice (C57BL/6 N), thereby elucidating potential therapeutic target(s). Increased calpain expression was found localized to tyrosine hydroxylase (TH+) neurons in SN with significantly increased TUNEL-positive neurons in SN and spinal cord neurons in MPTP mice. Inflammatory markers Cox-2, caspase-1, and NOS-2 were significantly upregulated in MPTP mouse spinal cord as compared to control. These parameters correlated with the activation of astrocytes, microglia, infiltration of CD4+/CD8+ T cells, and macrophages. We found that subpopulations of CD4+ cells (Th1 and Tregs) were differentially expanded in MPTP mice, which could be regulated by inhibition of calpain with the potent inhibitor calpeptin. Pretreatment with calpeptin (25 μg/kg, i.p.) attenuated glial activation, T cell infiltration, nigral dopaminergic degeneration in SN, and neuronal death in spinal cord. Importantly, calpeptin ameliorated MPTP-induced altered gait parameters (e.g., reduced stride length and increased stride frequency) as demonstrated by analyses of spatiotemporal gait indices using ventral plane videography. These findings suggest that calpain plays a pivotal role in MPTP-induced nigral and extranigral neurodegenerative processes and may be a valid therapeutic target in PD.Keywords
This publication has 78 references indexed in Scilit:
- Alzheimer's disease pattern of brain atrophy predicts cognitive decline in Parkinson's diseaseBrain, 2011
- Calpain inhibition protected spinal cord motoneurons against 1-methyl-4-phenylpyridinium ion and rotenoneNeuroscience, 2011
- Neuroprotective effects of genistein in VSC4.1 motoneurons exposed to activated microglial cytokinesNeurochemistry International, 2011
- Tracking extranigral degeneration in animal models of Parkinson’s disease: quest for effective therapeutic strategiesJournal of Neurochemistry, 2011
- Regulation of Th1/Th17 cytokines and IDO gene expression by inhibition of calpain in PBMCs from MS patientsJournal of Neuroimmunology, 2010
- Cholinergic mesencephalic neurons are involved in gait and postural disorders in Parkinson diseaseJournal of Clinical Investigation, 2010
- Reactive microgliosis: extracellular μ-calpain and microglia-mediated dopaminergic neurotoxicityBrain, 2010
- Innate and Adaptive Immunity for the Pathobiology of Parkinson's DiseaseAntioxidants & Redox Signaling, 2009
- Involvement of calpain in the process of Jurkat T cell chemotaxisJournal of Neuroscience Research, 2008
- The parkinsonian neurotoxin rotenone activates calpain and caspase-3 leading to motoneuron degeneration in spinal cord of Lewis ratsNeuroscience, 2007